Anti-platelet aggregation

"Anti-platelet aggregation" refers to the inhibition of the process by which platelets clump together to form a platelet plug, the initial step of hemostasis following vascular injury. This is not a single molecular entity, but an umbrella term for a therapeutic effect achieved by targeting several specific proteins on the platelet surface, notably: - P2Y₁₂ receptor (by drugs like clopidogrel, prasugrel, ticagrelor) - Glycoprotein IIb/IIIa receptor (by abciximab, eptifibatide, tirofiban) - Thromboxane A₂ receptor or synthase (by aspirin and thromboxane inhibitors) - Protease-activated receptor-1 (PAR-1, targeted by vorapaxar) Each of these targets has distinct molecular classifications and clinical roles. Inhibition of platelet aggregation prevents clot formation in diseases like myocardial infarction and stroke[2][5][3][8]. Since "anti-platelet aggregation" is a pharmacological action and not a target itself, a proper structured entry would need to identify the underlying molecular target(s) relevant to a particular drug or mechanism. For structured data of molecular targets relevant to anti-platelet aggregation, examples would include: - canonical_name: P2Y₁₂ receptor - canonical_name: Glycoprotein IIb/IIIa (integrin αIIbβ3) - canonical_name: Thromboxane A₂ synthase "Anti-platelet aggregation" is best viewed as a therapeutic class or mechanism and should not be used as a canonical molecular target. For further structured information, the specific underlying molecular entity must be named[2][5][3].

Other names

Anti-plateletPlatelet aggregation inhibitorAntiplatelet